US Stocks Today: Top Gainers, Losers and Market Movers
Neogen (NEOG) reported Q1 FY27 revenue up 6.5% to $222.8M, raised full-year guidance, but shares fell 3.7%. Penguin Solutions (PENG) beat Q4 estimates, raised FY27 outlook, shares up 13.9%. Constellation Brands (STZ) topped Q2 estimates, shares up 3.5%. Hess Midstream (HESM) shares dropped 10.3% after restructuring deal with Chevron (CVX) and lowered 2027 outlook. SRX Global (SRXH) shares rose 4% after $1M stock deal to acquire CERo Therapeutics.
How this was made
The 30-second read
Why it matters
Each company’s stock reacted sharply to its own news, providing distinct trading opportunities.
Market read
The mixed earnings and corporate actions create short‑term trading signals across biotech, AI, beverage, energy, and biotech M&A sectors.
What to watch
Penguin's rapid AI demand growth could face supply constraints; Hess Midstream's restructuring may unlock longer‑term value despite short‑term pain.
Background
The article aggregates several same‑day corporate updates, primarily earnings releases and a restructuring announcement.
Ticker impact
Neogen reported Q1 FY27 revenue up 6.5% and raised guidance, but its shares fell 3.7% intraday.
likely further downside as market doubts guidance sustainability
Guidance raise was modest and preceded by a sharp prior decline, causing investors to remain skeptical.
Penguin Solutions posted a Q4 FY26 beat and raised FY27 outlook, sending the stock up about 14% intraday.
upward momentum expected as investors price in high growth outlook
Beat estimates and a bright FY27 outlook with record revenue underpin a bullish sentiment.
Constellation Brands beat Q2 FY27 earnings estimates and reaffirmed guidance, lifting the stock about 3.5% intraday.
moderate upside as market digests solid performance
Beat and steady guidance reinforce confidence, but move is modest.
Hess Midstream announced a restructuring with Chevron that lowered its 2027 outlook, causing the stock to fall roughly 10% intraday.
downward pressure likely to continue as earnings outlook is cut
Significant outlook downgrade and restructuring uncertainty drive sell‑off.
SRX Global disclosed a $1 million stock deal to acquire CERo Therapeutics, sending the shares up about 4% intraday.
upward bias as market views the deal as value‑adding
The acquisition expands SRX's pipeline and is perceived positively despite its small size.
Market effects
Earnings beats in AI infrastructure and consumer beverages support sector optimism; midstream restructuring adds pressure to energy infrastructure.
U.S. equities see mixed moves as individual earnings dominate.
Limited to U.S. markets; no broader macro impact.
Counterpoint
Neogen's guidance raise may be insufficient; investors could short on lingering doubts.
Key entities
- companyNeogen Corporation
Biotech firm reporting Q1 FY27 results.
- companyPenguin Solutions Inc.
AI infrastructure provider reporting Q4 FY26 results.
- companyConstellation Brands Inc.
Beverage conglomerate reporting Q2 FY27 results.
- companyHess Midstream Partners LP
Midstream energy firm announcing restructuring with Chevron.
- companySRX Global Inc.
Biotech acquiring CERo Therapeutics.
